Xin Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xin Huang has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Xinyu He
School of Computer and Information Technology, Liaoning Normal University, Dalian, Liaoning, China
6 shared publicationsBenzhe Su
School of Computer Science and Technology, Dalian University of Technology, Dalian, China
5 shared publicationsYang Zhou
Ningbo Institute of Innovation for Combined Medicine and Engineering, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, Zhejiang, China
5 shared publicationsBing Liu
School of Mathematics and Information Science, Anshan Normal University, Anshan, Liaoning 114007, P. R. China
4 shared publications- Xiaohui Lin
School of Computer Science and Technology, Dalian University of Technology, Dalian 116024, China
4 shared publications - Benzhe Su
School of Computer Science and Technology, Dalian University of Technology, Liaoning, China
2 shared publications
Latest Publications
- 27 March 2026
- Published by Bentham Science Publishers Ltd. in Combinatorial Chemistry & High Throughput Screening
- Vol. 29
A Data-driven Approach for Biomarker Discovery based on U-centered Distance Correlation Network: Multi-omics Warning Signals for Non-small Cell Lung Cancer
Introduction/Objective: Lung cancer is the leading cause of cancer-related mortality worldwide, and non-small cell lung cancer (NSCLC) accounts for the majority of cases. Alterations in metabolic activities play important roles in NSCLC development, wherein related genes and metabolites interact with each other, involving multiple forms. Methods: To comprehensively understand the pathogenic mechanisms and improve the performance of clinical early, precise diagnosis, this study proposed a data-driven approach for biomarker discovery based on U-centered distance correlation network (DCN) to investigate NSCLC metabolism-related reactions. In DCN, changes in molecular relationships during NSCLC initiation and progression are measured using the t-statistics of U-centered distance correlation for network construction, in which prospective warning signals representing NSCLC onset can be identified without human intervention. Additionally, the network construction criterion in DCN can precisely and effectively capture both linear and nonlinear molecular relationships in simple and biologically relevant manners. Results: DCN was successfully employed to analyze NSCLC metabolism-related metabolomics and genomics datasets. Statistical analyses confirmed that compared with other algorithms, the gene and metabolite biomarker panels identified by DCN provided more reliable diagnostic capabilities for clinical NSCLC detection. Biological analyses revealed that disturbed energy metabolism and lipid metabolism occurred during tumor cell proliferation and growth in NSCLC patients. Discussion: The gene ASPA and metabolite aspartic acid were significantly decreased in NSCLC samples, suggesting that the corresponding amino acid metabolic activities were intricately linked to NSCLC progression. Conclusion: These findings demonstrated that DCN can further facilitate NSCLC studies to improve clinical outcomes in patients.
- 27 March 2026
- Published by Bentham Science Publishers Ltd. in Combinatorial Chemistry & High Throughput Screening
- Vol. 29
A Data-driven Approach for Biomarker Discovery based on U-centered Distance Correlation Network: Multi-omics Warning Signals for Non-small Cell Lung Cancer
Introduction/Objective: Lung cancer is the leading cause of cancer-related mortality worldwide, and non-small cell lung cancer (NSCLC) accounts for the majority of cases. Alterations in metabolic activities play important roles in NSCLC development, wherein related genes and metabolites interact with each other, involving multiple forms. Methods: To comprehensively understand the pathogenic mechanisms and improve the performance of clinical early, precise diagnosis, this study proposed a data-driven approach for biomarker discovery based on U-centered distance correlation network (DCN) to investigate NSCLC metabolism-related reactions. In DCN, changes in molecular relationships during NSCLC initiation and progression are measured using the t-statistics of U-centered distance correlation for network construction, in which prospective warning signals representing NSCLC onset can be identified without human intervention. Additionally, the network construction criterion in DCN can precisely and effectively capture both linear and nonlinear molecular relationships in simple and biologically relevant manners. Results: DCN was successfully employed to analyze NSCLC metabolism-related metabolomics and genomics datasets. Statistical analyses confirmed that compared with other algorithms, the gene and metabolite biomarker panels identified by DCN provided more reliable diagnostic capabilities for clinical NSCLC detection. Biological analyses revealed that disturbed energy metabolism and lipid metabolism occurred during tumor cell proliferation and growth in NSCLC patients. Discussion: The gene ASPA and metabolite aspartic acid were significantly decreased in NSCLC samples, suggesting that the corresponding amino acid metabolic activities were intricately linked to NSCLC progression. Conclusion: These findings demonstrated that DCN can further facilitate NSCLC studies to improve clinical outcomes in patients.
- Open Access
- 22 May 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1538074
Machine learning modeling for the risk of acute kidney injury in inpatients receiving amikacin and etimicin
Background: Acute kidney injury (AKI) is a significant concern among hospitalized patients receiving aminoglycosides. Identifying the risk factors associated with aminoglycoside-induced AKI and developing machine learning models are imperative in clinical practice.Objective: This study aims to identify the risk factors associated with AKI in hospitalized patients receiving aminoglycosides, and develop machine learning models for evaluation of the AKI risk in these patients.Methods: This study retrospectively analyzed 7,028 hospitalized patients who received treatment with amikacin or etimicin between 2018 and 2020. According to the type of medication used, patients were divided into amikacin group (n = 307) and etimicin group (n = 6,901). Univariate analyses and the least absolute shrinkage and selection operator algorithm were used to screen risk factors and construct the model. The machine learning models were developed using five different algorithms, including logistic regression (LR), random forest (RF), gradient boosting machine (GBM), extreme gradient boosting model (XGBoost), and light gradient boosting machine (Light GBM).Results: The XGBoost model exhibited the most superior performance in predicting amikacin-associated AKI among the developed machine learning models. For the training set, the area under the receiver-operator characteristic curve (AUC) was 0.916, and for the test set, it was 0.841. The model can be accessed online. Regarding AKI risk in etimicin-treated patients, the GBM model demonstrated the best overall performance, with AUC values of 0.886 for the training set and 0.900 for the test set. The model was also made available online.Conclusion: These predictive models may offer a valuable tool for estimating the risk of AKI in patients receiving amikacin or etimicin, facilitating clinical decision-making and aiding in the prevention of AKI.Trial Registration: ClinicalTrials.gov NCT05533593.
- 22 May 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1538074
Open AccessMachine learning modeling for the risk of acute kidney injury in inpatients receiving amikacin and etimicin
Background: Acute kidney injury (AKI) is a significant concern among hospitalized patients receiving aminoglycosides. Identifying the risk factors associated with aminoglycoside-induced AKI and developing machine learning models are imperative in clinical practice.Objective: This study aims to identify the risk factors associated with AKI in hospitalized patients receiving aminoglycosides, and develop machine learning models for evaluation of the AKI risk in these patients.Methods: This study retrospectively analyzed 7,028 hospitalized patients who received treatment with amikacin or etimicin between 2018 and 2020. According to the type of medication used, patients were divided into amikacin group (n = 307) and etimicin group (n = 6,901). Univariate analyses and the least absolute shrinkage and selection operator algorithm were used to screen risk factors and construct the model. The machine learning models were developed using five different algorithms, including logistic regression (LR), random forest (RF), gradient boosting machine (GBM), extreme gradient boosting model (XGBoost), and light gradient boosting machine (Light GBM).Results: The XGBoost model exhibited the most superior performance in predicting amikacin-associated AKI among the developed machine learning models. For the training set, the area under the receiver-operator characteristic curve (AUC) was 0.916, and for the test set, it was 0.841. The model can be accessed online. Regarding AKI risk in etimicin-treated patients, the GBM model demonstrated the best overall performance, with AUC values of 0.886 for the training set and 0.900 for the test set. The model was also made available online.Conclusion: These predictive models may offer a valuable tool for estimating the risk of AKI in patients receiving amikacin or etimicin, facilitating clinical decision-making and aiding in the prevention of AKI.Trial Registration: ClinicalTrials.gov NCT05533593.
- 8 April 2025
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Computational Biology and Bioinformatics
- Vol. 22  (4) , 1553-1563
Multiomics Data Integration of Lipid Metabolism in Hepatocellular Carcinoma Studies Using Bioinformatics Networks Based on Vertical and Horizontal Comparisons
Exploring changes in lipid metabolism is helpful for providing unique insight into hepatocellular carcinoma (HCC) pathogenesis mechanisms and early hepatocarcinogenesis. However, lipid metabolism involves different omics molecular interactions by means of both linear and nonlinear forms. Thus, we proposed a novel network construction method based on molecular pair evaluation from linear and nonlinear viewpoints (PELN) for clinical studies. In PELN, molecular relationships were explored in depth by horizontal comparison (linear relationship) and vertical comparison (nonlinear relationship) to reflect disease development for biomarker discovery. In the score calculated by PELN, case ratios and case frequencies were used to comprehensively measure the discriminative ability of the molecular pairs, which can reduce the influence of sampling variability resulting from different subjects. HCC genomics and metabolomics datasets related to lipid metabolism were analyzed by PELN, and the selected network warning signals were shown to effectively predict cancer onset. The experimental results showed that compared with other network methods, including DMNC, DNB-HC, ATSD-DN and MN-PCC, PELN was more robust and precise for distinguishing HCC samples from non-HCC samples. Further analysis using statistical methods demonstrated that studying changes in lipid metabolism using PELN based on multiomics data can help to further understand the pathological mechanisms associated with HCC development, contributing to early diagnosis and affecting clinical prognosis.
- 8 April 2025
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Computational Biology and Bioinformatics
- Vol. 22  (4) , 1553-1563
Multiomics Data Integration of Lipid Metabolism in Hepatocellular Carcinoma Studies Using Bioinformatics Networks Based on Vertical and Horizontal Comparisons
Exploring changes in lipid metabolism is helpful for providing unique insight into hepatocellular carcinoma (HCC) pathogenesis mechanisms and early hepatocarcinogenesis. However, lipid metabolism involves different omics molecular interactions by means of both linear and nonlinear forms. Thus, we proposed a novel network construction method based on molecular pair evaluation from linear and nonlinear viewpoints (PELN) for clinical studies. In PELN, molecular relationships were explored in depth by horizontal comparison (linear relationship) and vertical comparison (nonlinear relationship) to reflect disease development for biomarker discovery. In the score calculated by PELN, case ratios and case frequencies were used to comprehensively measure the discriminative ability of the molecular pairs, which can reduce the influence of sampling variability resulting from different subjects. HCC genomics and metabolomics datasets related to lipid metabolism were analyzed by PELN, and the selected network warning signals were shown to effectively predict cancer onset. The experimental results showed that compared with other network methods, including DMNC, DNB-HC, ATSD-DN and MN-PCC, PELN was more robust and precise for distinguishing HCC samples from non-HCC samples. Further analysis using statistical methods demonstrated that studying changes in lipid metabolism using PELN based on multiomics data can help to further understand the pathological mechanisms associated with HCC development, contributing to early diagnosis and affecting clinical prognosis.
- Open Access
- 18 December 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13  (1) , 1-13
Multiomics characterization of fatty acid metabolism for the clinical management of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a prevalent malignancy and there is a lack of effective biomarkers for HCC diagnosis. Living organisms are complex, and different omics molecules interact with each other to implement various biological functions. Genomics and metabolomics, which are the top and bottom of systems biology, play an important role in HCC clinical management. Fatty acid metabolism is associated with malignancy, prognosis, and immune phenotype in cancer, which is a potential hallmark in malignant tumors. In this study, the genes and metabolites related to fatty acid metabolism were thoroughly investigated by a dynamic network construction algorithm named EWS-DDA for the early diagnosis and prognosis of HCC. Three gene ratios and eight metabolite ratios were identified by EWS-DDA as potential biomarkers for HCC clinical management. Further analysis using biological analysis, statistical analysis and document validation in the discovery and validation sets suggested that the selected potential biomarkers had great clinical prognostic value and helped to achieve effective early diagnosis of HCC. Experimental results suggested that in-depth evaluation of fatty acid metabolism from different omics viewpoints can facilitate the further understanding of pathological alterations associated with HCC characteristics, improving the performance of early diagnosis and clinical prognosis.
- 18 December 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13  (1) , 1-13
Open AccessMultiomics characterization of fatty acid metabolism for the clinical management of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a prevalent malignancy and there is a lack of effective biomarkers for HCC diagnosis. Living organisms are complex, and different omics molecules interact with each other to implement various biological functions. Genomics and metabolomics, which are the top and bottom of systems biology, play an important role in HCC clinical management. Fatty acid metabolism is associated with malignancy, prognosis, and immune phenotype in cancer, which is a potential hallmark in malignant tumors. In this study, the genes and metabolites related to fatty acid metabolism were thoroughly investigated by a dynamic network construction algorithm named EWS-DDA for the early diagnosis and prognosis of HCC. Three gene ratios and eight metabolite ratios were identified by EWS-DDA as potential biomarkers for HCC clinical management. Further analysis using biological analysis, statistical analysis and document validation in the discovery and validation sets suggested that the selected potential biomarkers had great clinical prognostic value and helped to achieve effective early diagnosis of HCC. Experimental results suggested that in-depth evaluation of fatty acid metabolism from different omics viewpoints can facilitate the further understanding of pathological alterations associated with HCC characteristics, improving the performance of early diagnosis and clinical prognosis.
- Open Access
- 22 November 2023
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 25  (1)
Identifying the potential miRNA biomarkers based on multi-view networks and reinforcement learning for diseases
MicroRNAs (miRNAs) play important roles in the occurrence and development of diseases. However, it is still challenging to identify the effective miRNA biomarkers for improving the disease diagnosis and prognosis. In this study, we proposed the miRNA data analysis method based on multi-view miRNA networks and reinforcement learning, miRMarker, to define the potential miRNA disease biomarkers. miRMarker constructs the cooperative regulation network and functional similarity network based on the expression data and known miRNA–disease relations, respectively. The cooperative regulation of miRNAs was evaluated by measuring the changes of relative expression. Natural language processing was introduced for calculating the miRNA functional similarity. Then, miRMarker integrates the multi-view miRNA networks and defines the informative miRNA modules through a reinforcement learning strategy. We compared miRMarker with eight efficient data analysis methods on nine transcriptomics datasets to show its superiority in disease sample discrimination. The comparison results suggested that miRMarker outperformed other data analysis methods in receiver operating characteristic analysis. Furthermore, the defined miRNA modules of miRMarker on colorectal cancer data not only show the excellent performance of cancer sample discrimination but also play significant roles in the cancer-related pathway disturbances. The experimental results indicate that miRMarker can build the robust miRNA interaction network by integrating the multi-view networks. Besides, exploring the miRNA interaction network using reinforcement learning favors defining the important miRNA modules. In summary, miRMarker can be a hopeful tool in biomarker identification for human diseases.
- 22 November 2023
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 25  (1)
Open AccessIdentifying the potential miRNA biomarkers based on multi-view networks and reinforcement learning for diseases
MicroRNAs (miRNAs) play important roles in the occurrence and development of diseases. However, it is still challenging to identify the effective miRNA biomarkers for improving the disease diagnosis and prognosis. In this study, we proposed the miRNA data analysis method based on multi-view miRNA networks and reinforcement learning, miRMarker, to define the potential miRNA disease biomarkers. miRMarker constructs the cooperative regulation network and functional similarity network based on the expression data and known miRNA–disease relations, respectively. The cooperative regulation of miRNAs was evaluated by measuring the changes of relative expression. Natural language processing was introduced for calculating the miRNA functional similarity. Then, miRMarker integrates the multi-view miRNA networks and defines the informative miRNA modules through a reinforcement learning strategy. We compared miRMarker with eight efficient data analysis methods on nine transcriptomics datasets to show its superiority in disease sample discrimination. The comparison results suggested that miRMarker outperformed other data analysis methods in receiver operating characteristic analysis. Furthermore, the defined miRNA modules of miRMarker on colorectal cancer data not only show the excellent performance of cancer sample discrimination but also play significant roles in the cancer-related pathway disturbances. The experimental results indicate that miRMarker can build the robust miRNA interaction network by integrating the multi-view networks. Besides, exploring the miRNA interaction network using reinforcement learning favors defining the important miRNA modules. In summary, miRMarker can be a hopeful tool in biomarker identification for human diseases.
- 27 December 2022
- Published by World Scientific Pub Co Pte Ltd in Journal of Bioinformatics and Computational Biology
- Vol. 20  (06) , 2250027
A network-based dynamic criterion for identifying prediction and early diagnosis biomarkers of complex diseases
Lung adenocarcinoma (LUAD) seriously threatens human health and generally results from dysfunction of relevant module molecules, which dynamically change with time and conditions, rather than that of an individual molecule. In this study, a novel network construction algorithm for identifying early warning network signals (IEWNS) is proposed for improving the performance of LUAD early diagnosis. To this end, we theoretically derived a dynamic criterion, namely, the relationship of variation (RV), to construct dynamic networks. RV infers correlation [ ] statistics to measure dynamic changes in molecular relationships during the process of disease development. Based on the dynamic networks constructed by IEWNS, network warning signals used to represent the occurrence of LUAD deterioration can be defined without human intervention. IEWNS was employed to perform a comprehensive analysis of gene expression profiles of LUAD from The Cancer Genome Atlas (TCGA) database and the Gene Expression Omnibus (GEO) database. The experimental results suggest that the potential biomarkers selected by IEWNS can facilitate a better understanding of pathogenetic mechanisms and help to achieve effective early diagnosis of LUAD. In conclusion, IEWNS provides novel insight into the initiation and progression of LUAD and helps to define prospective biomarkers for assessing disease deterioration.
- 27 December 2022
- Published by World Scientific Pub Co Pte Ltd in Journal of Bioinformatics and Computational Biology
- Vol. 20  (06) , 2250027
A network-based dynamic criterion for identifying prediction and early diagnosis biomarkers of complex diseases
Lung adenocarcinoma (LUAD) seriously threatens human health and generally results from dysfunction of relevant module molecules, which dynamically change with time and conditions, rather than that of an individual molecule. In this study, a novel network construction algorithm for identifying early warning network signals (IEWNS) is proposed for improving the performance of LUAD early diagnosis. To this end, we theoretically derived a dynamic criterion, namely, the relationship of variation (RV), to construct dynamic networks. RV infers correlation [ ] statistics to measure dynamic changes in molecular relationships during the process of disease development. Based on the dynamic networks constructed by IEWNS, network warning signals used to represent the occurrence of LUAD deterioration can be defined without human intervention. IEWNS was employed to perform a comprehensive analysis of gene expression profiles of LUAD from The Cancer Genome Atlas (TCGA) database and the Gene Expression Omnibus (GEO) database. The experimental results suggest that the potential biomarkers selected by IEWNS can facilitate a better understanding of pathogenetic mechanisms and help to achieve effective early diagnosis of LUAD. In conclusion, IEWNS provides novel insight into the initiation and progression of LUAD and helps to define prospective biomarkers for assessing disease deterioration.
- 20 May 2022
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE/ACM Transactions on Computational Biology and Bioinformatics
- Vol. 20  (2) , 923-931
Dynamic Network Construction for Identifying Early Warning Signals Based On a Data-Driven Approach: Early Diagnosis Biomarker Discovery for Gastric Cancer
During the development of complex diseases, there is a critical transition from one status to another at a tipping point, which can be an early indicator of disease deterioration. To effectively enhance the performance of early risk identification, a novel dynamic network construction algorithm for identifying early warning signals based on a data-driven approach (EWS-DDA) was proposed. In EWS-DDA, the shrunken centroid was introduced to measure dynamic expression changes in assumed pathway reactions during the progression of complex disease for network construction and to define early warning signals by means of a data-driven approach. We applied EWS-DDA to perform a comprehensive analysis of gene expression profiles of gastric cancer (GC) from The Cancer Genome Atlas database and the Gene Expression Omnibus database. Six crucial genes were selected as potential biomarkers for the early diagnosis of GC. The experimental results of statistical analysis and biological analysis suggested that the six genes play important roles in GC occurrence and development. Then, EWS-DDA was compared with other state-of-the-art network methods to validate its performance. The theoretical analysis and comparison results suggested that EWS-DDA has great potential for a more complete presentation of disease deterioration and effective extraction of early warning information.
- 20 May 2022
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE/ACM Transactions on Computational Biology and Bioinformatics
- Vol. 20  (2) , 923-931
Dynamic Network Construction for Identifying Early Warning Signals Based On a Data-Driven Approach: Early Diagnosis Biomarker Discovery for Gastric Cancer
During the development of complex diseases, there is a critical transition from one status to another at a tipping point, which can be an early indicator of disease deterioration. To effectively enhance the performance of early risk identification, a novel dynamic network construction algorithm for identifying early warning signals based on a data-driven approach (EWS-DDA) was proposed. In EWS-DDA, the shrunken centroid was introduced to measure dynamic expression changes in assumed pathway reactions during the progression of complex disease for network construction and to define early warning signals by means of a data-driven approach. We applied EWS-DDA to perform a comprehensive analysis of gene expression profiles of gastric cancer (GC) from The Cancer Genome Atlas database and the Gene Expression Omnibus database. Six crucial genes were selected as potential biomarkers for the early diagnosis of GC. The experimental results of statistical analysis and biological analysis suggested that the six genes play important roles in GC occurrence and development. Then, EWS-DDA was compared with other state-of-the-art network methods to validate its performance. The theoretical analysis and comparison results suggested that EWS-DDA has great potential for a more complete presentation of disease deterioration and effective extraction of early warning information.
- Open Access
- 31 March 2022
- Published by Wiley
A network-based dynamic criterion for early warning signal discovery: Prediction and early diagnosis for lung adenocarcinoma
Complex diseases generally result from dysfunction of relevant module molecules, which dynamically change with time and conditions, rather than that of an individual molecule. In this study, a novel network construction algorithm for identifying early warning network signals (namely, IEWNS) is proposed for improving the performance of early diagnosis. To this end, we theoretically derived a network-based dynamic criterion, namely, the relationship of variation (RV), to construct dynamic networks. RV infers correlation t statistics to measure dynamic changes in molecular relationships during the process of disease development. Based on the dynamic networks constructed by IEWNS, early warning network signals used to represent the occurrence of complex disease deterioration can be defined without human intervention. IEWNS was employed to perform a comprehensive analysis of gene expression profiles of lung adenocarcinoma (LUAD) from The Cancer Genome Atlas database and the Gene Expression Omnibus database. The experimental results suggest that the network biomarker selected by IEWNS can facilitate a better understanding of pathogenetic mechanisms and help to achieve effective early diagnosis of LUAD. In conclusion, IEWNS provides novel insight into the pathogenic mechanisms of complex diseases and helps to define prospective biomarkers for assessing disease deterioration.
- 31 March 2022
- Published by Wiley
Open AccessA network-based dynamic criterion for early warning signal discovery: Prediction and early diagnosis for lung adenocarcinoma
Complex diseases generally result from dysfunction of relevant module molecules, which dynamically change with time and conditions, rather than that of an individual molecule. In this study, a novel network construction algorithm for identifying early warning network signals (namely, IEWNS) is proposed for improving the performance of early diagnosis. To this end, we theoretically derived a network-based dynamic criterion, namely, the relationship of variation (RV), to construct dynamic networks. RV infers correlation t statistics to measure dynamic changes in molecular relationships during the process of disease development. Based on the dynamic networks constructed by IEWNS, early warning network signals used to represent the occurrence of complex disease deterioration can be defined without human intervention. IEWNS was employed to perform a comprehensive analysis of gene expression profiles of lung adenocarcinoma (LUAD) from The Cancer Genome Atlas database and the Gene Expression Omnibus database. The experimental results suggest that the network biomarker selected by IEWNS can facilitate a better understanding of pathogenetic mechanisms and help to achieve effective early diagnosis of LUAD. In conclusion, IEWNS provides novel insight into the pathogenic mechanisms of complex diseases and helps to define prospective biomarkers for assessing disease deterioration.